Eli Lilly Commits $856M in Biobucks to Gate Bioscience for New Class of Medicines

The collaboration focuses on ‘molecular gates,’ a class of molecules that the startup company Gate Bioscience says can stop pathogenic proteins from leaving the cell.

Scroll to Top